Jin W, Lu Y, Lu J, Wang Z, Yan Y, Liang B
Front Genet. 2025; 16:1476092.
PMID: 40041860
PMC: 11876384.
DOI: 10.3389/fgene.2025.1476092.
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E
J Hematol Oncol. 2025; 18(1):6.
PMID: 39806516
PMC: 11733683.
DOI: 10.1186/s13045-024-01634-6.
Salminen A
Biogerontology. 2024; 26(1):19.
PMID: 39643709
PMC: 11624233.
DOI: 10.1007/s10522-024-10164-0.
Vecchiotti D, Clementi L, Cornacchia E, Di Vito Nolfi M, Verzella D, Capece D
Cancers (Basel). 2024; 16(18).
PMID: 39335188
PMC: 11430343.
DOI: 10.3390/cancers16183215.
Stacchiotti S, Martini S, Pasquali S, Frezza A, Beretta A, Percio S
Clin Cancer Res. 2024; 30(22):5122-5137.
PMID: 39283723
PMC: 11565171.
DOI: 10.1158/1078-0432.CCR-23-3991.
Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution.
Zhang F, Ma Y, Li D, Wei J, Chen K, Zhang E
J Hematol Oncol. 2024; 17(1):80.
PMID: 39223656
PMC: 11367794.
DOI: 10.1186/s13045-024-01600-2.
Tumor-Agnostic Therapy-The Final Step Forward in the Cure for Human Neoplasms?.
El-Sayed M, Bianco J, Li Y, Fabian Z
Cells. 2024; 13(12.
PMID: 38920700
PMC: 11201516.
DOI: 10.3390/cells13121071.
Cancer associated fibroblasts modulate the cytotoxicity of anti-cancer drugs in breast cancer: An in vitro study.
Kashyap D, Bhattacharya S, Irinike S, Khare S, Das A, Singh G
Breast Dis. 2024; 43(1):25-36.
PMID: 38517765
PMC: 10977379.
DOI: 10.3233/BD-230011.
Stromal-derived MAOB promotes prostate cancer growth and progression.
Pu T, Wang J, Wei J, Zeng A, Zhang J, Chen J
Sci Adv. 2024; 10(6):eadi4935.
PMID: 38335292
PMC: 10857382.
DOI: 10.1126/sciadv.adi4935.
Targeting dysregulated lipid metabolism in the tumor microenvironment.
Kim D, Song N, Yim H
Arch Pharm Res. 2023; 46(11-12):855-881.
PMID: 38060103
PMC: 10725365.
DOI: 10.1007/s12272-023-01473-y.
Cancer-associated fibroblast-related prognostic signature predicts prognosis and immunotherapy response in pancreatic adenocarcinoma based on single-cell and bulk RNA-sequencing.
Chen Y, Deng Q, Chen H, Yang J, Chen Z, Li J
Sci Rep. 2023; 13(1):16408.
PMID: 37775715
PMC: 10541448.
DOI: 10.1038/s41598-023-43495-y.
Advances in landscape and related therapeutic targets of the prostate tumor microenvironment.
Li D, Xu W, Chang Y, Xiao Y, He Y, Ren S
Acta Biochim Biophys Sin (Shanghai). 2023; 55(6):956-973.
PMID: 37294106
PMC: 10326416.
DOI: 10.3724/abbs.2023092.
The Interplay between T Cells and Cancer: The Basis of Immunotherapy.
Chen C, Liu X, Chang C, Wang H, Wang R
Genes (Basel). 2023; 14(5).
PMID: 37239368
PMC: 10218245.
DOI: 10.3390/genes14051008.
Systemic Reprogramming of Endothelial Cell Signaling in Metastasis and Cachexia.
Preuss S, Grieshober D, Augustin H
Physiology (Bethesda). 2023; 38(4).
PMID: 37222464
PMC: 10281790.
DOI: 10.1152/physiol.00001.2023.
New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer.
Lin M, Sun X, Lv L
Mol Ther Oncolytics. 2023; 29:91-106.
PMID: 37215386
PMC: 10199166.
DOI: 10.1016/j.omto.2023.04.007.
Epigenetic Modifications in Prostate Cancer Metastasis and Microenvironment.
Zhang S, Shen T, Zeng Y
Cancers (Basel). 2023; 15(8).
PMID: 37190171
PMC: 10137161.
DOI: 10.3390/cancers15082243.
Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer.
Eickelschulte S, Riediger A, Angeles A, Janke F, Duensing S, Sultmann H
Cancers (Basel). 2022; 14(24).
PMID: 36551580
PMC: 9777028.
DOI: 10.3390/cancers14246094.
Current Pathology Model of Pancreatic Cancer.
Szymonski K, Milian-Ciesielska K, Lipiec E, Adamek D
Cancers (Basel). 2022; 14(9).
PMID: 35565450
PMC: 9105915.
DOI: 10.3390/cancers14092321.
Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance.
Ge R, Wang Z, Cheng L
NPJ Precis Oncol. 2022; 6(1):31.
PMID: 35508696
PMC: 9068628.
DOI: 10.1038/s41698-022-00272-w.
Tumor-Derived Extracellular Vesicles Activate Normal Human Fibroblasts to a Cancer-Associated Fibroblast-Like Phenotype, Sustaining a Pro-Tumorigenic Microenvironment.
Giusti I, Di Francesco M, Poppa G, Esposito L, DAscenzo S, Dolo V
Front Oncol. 2022; 12:839880.
PMID: 35280782
PMC: 8905682.
DOI: 10.3389/fonc.2022.839880.